Investigating incretin-based therapies as a novel treatment for depression in type 2 diabetes: Findings from the South London Diabetes (SOUL-D) Study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26137918.
- Also identified by DOI 10.1016/j.pcd.2015.06.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We aimed to investigate the association between incretin-based therapies and 1-year change in depressive symptoms in a cohort of 1735 patients with newly diagnosed type 2 diabetes. The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism.
Medical subject headings
- Antidepressive Agents
- Depression
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Incretins